HSV-1 amplicon as a novel vector for gene transfer into refractory tumors
Project/Area Number |
24501351
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Clinical oncology
|
Research Institution | Nagoya University |
Principal Investigator |
GOSHIMA Fumi 名古屋大学, 医学(系)研究科(研究院), 助教 (70201499)
|
Co-Investigator(Kenkyū-buntansha) |
KIMURA Hiroshi 名古屋大学, 大学院医学系研究科, 教授 (30303621)
KAMAKURA Maki 名古屋大学, 医学(系)研究科(研究院), その他 (80437003)
|
Research Collaborator |
ESAKI Shinichi 名古屋市立大学, 大学院医学研究科, 助教 (20620983)
|
Project Period (FY) |
2012-04-01 – 2015-03-31
|
Project Status |
Completed (Fiscal Year 2014)
|
Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 遺伝子治療 / ウイルス / アンプリコン / 癌 |
Outline of Final Research Achievements |
We made an HSV amplicon expressing murine GM-CSF to strengthen anti-tumor immune response for the treatment of ovarian cancer with intraperitoneal dissemination. Intraperitoneal injection of mGM-CSF amplicon prolonged survival and decreased intraperitoneal dissemination. Immunohistochemical staining revealed the infiltration of CD4- and CD8-positive cells into the peritoneal tumors. Murine splenic cells after each treatment were stimulated with HM-1 cells, and the strongest immune response was observed in the mice that received mGM-CSF amplicon injections. Now we have made an HSV amplicon expressing murine IL-2 and confirmed expression of IL2 in the infected cells.
|
Report
(4 results)
Research Products
(6 results)